DiaMedica Therapeutics Inc. (DMAC) Earnings Call Transcripts
DiaMedica Therapeutics Inc.'s Latest Earnings Call - March 31, 2026
In the fiscal year 2025 earnings call, DiaMedica Therapeutics Inc. (DMAC:US) reported a significant increase in cash reserves to $59.9 million, bolstered by a private placement and an at-the-market offering. The company highlighted promising interim results from its DM-199 program for preeclampsia, which demonstrated statistically significant reductions in blood pressure and improved vascular health without crossing the placental barrier. Management maintained guidance for the completion of the interim analysis for the ReMEDy2 stroke trial in the second half of 2026, indicating continued progress in their clinical pipeline despite rising operational costs.
Reported metrics
| Metric | Value |
|---|---|
| Cash and Short-term Investments | $59.9 million (beat) |
| Net Cash Used in Operating Activities | $29.1 million (miss) |
| R&D Expenses | $24.6 million (miss) |
| General and Administrative Expenses | $9.8 million (miss) |
| Enrollment in ReMEDy2 Trial | 70% of 200 participants (positive) |
Guidance from management
Management maintained guidance to complete the interim analysis for the ReMEDy2 trial in the second half of 2026, indicating confidence in enrollment progress and clinical timelines.
What management said
Sure. Yes, that's a fair question. The cause really was staffing difficulties that Cathy Cluver encountered at her site. We gave some extra financial backing not long ago. And now that a couple of new nurses have been brought on within the past few weeks, we expect enrollment will start climbing once more.
Regarding those — a handful of protocol amendments from us are moving through the process soon. As a result, we expect those 2 cohorts to kick off later in Q2. The Part 1a expansion study continues right now and should also wrap up during Q2.
What analysts pressed on
Analysts expressed concerns regarding the slow enrollment in the preeclampsia program and the challenges faced in meeting FDA requirements for reproductive toxicology studies. There is also apprehension about the rising operational costs impacting future profitability.
Main topics on the call
- Preeclampsia Program Progress — DiaMedica reported positive interim results from its Phase II trial for DM-199, showing 'statistically significant reductions in blood pressure' and improved uterine artery pulsatility index. Management emphasized that D...
- Stroke Trial Enrollment Momentum — The company noted 'encouraging enrollment momentum' in the ReMEDy2 trial, achieving almost 70% of the required 200 participants for the interim analysis. Management reiterated guidance to complete this analysis by the se...
- Financial Position Improvement — DiaMedica's cash and short-term investments increased to $59.9 million, up from $44.1 million in the prior year, primarily due to a successful capital raise. This robust cash position is expected to fund clinical studies...
- R&D Expense Increase — Research and development expenses rose to $24.6 million from $19.1 million year-over-year, driven by ongoing clinical trials and team expansions. This increase reflects the company's commitment to advancing its clinical ...
Read the full DiaMedica Therapeutics Inc. transcript (March 31, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (DMAC) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 27 calls on record spanning March 24, 2020 to November 13, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 DiaMedica Therapeutics Inc. earnings call transcripts on record, spanning March 24, 2020 to November 13, 2026. Based on this history, DiaMedica Therapeutics Inc. reports quarterly. The most recent call on file is dated November 13, 2026. The full list is below — each row opens the transcript.
- Ticker
- DMAC
- Exchange
- NASDAQ
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 27
- First call
- March 24, 2020
- Most recent
- November 13, 2026
- Reporting cadence
- quarterly